English Français

Medexus Pharmaceuticals, Inc. Medexus Pharmaceuticals, Inc.

  • English
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Business Development
  • Our Portfolio
    • Overview
    • Canadian Product Portfolio
    • US Product Portfolio
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Presentation
    • Financial Results
    • Stock Data
    • Governance
    • SEDAR+
  • Contact
  • Careers
  • English
  • Français

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
    • 2024 Annual Meeting
    • 2023 Annual Meeting
    • 2022 Annual Meeting
    • 2021 Annual Meeting
    • 2020 Annual Meeting
    • 2021 Special Meeting
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Presentation
  • Financial Results
  • Stock Data
    • TSX: MDP
    • OTCQX: MEDXF
    • Analyst Coverage
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEDAR+
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
  • 2024 Annual Meeting
  • 2023 Annual Meeting
  • 2022 Annual Meeting
  • 2021 Annual Meeting
  • 2020 Annual Meeting
  • 2021 Special Meeting
  • All Years
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • All Releases
  • Financial Releases
Apr 17, 2025 7:00am EDT

Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada

Apr 07, 2025 7:00am EDT

Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection

Mar 14, 2025 7:00am EDT

Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.

Feb 24, 2025 7:00am EST

Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection

Feb 05, 2025 5:30pm EST

Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States

Feb 04, 2025 7:00am EST

Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada

Jan 31, 2025 5:30pm EST

Medexus Schedules Third Fiscal Quarter 2025 Conference Call

Jan 31, 2025 8:38am EST

Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares

Jan 28, 2025 9:33am EST

Medexus Pharmaceuticals Announces Pricing of $30 Million Overnight Marketed Public Offering of Common Shares

Jan 27, 2025 4:03pm EST

Medexus Pharmaceuticals Announces Overnight Marketed Public Offering of Common Shares

RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...19
Next
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
© 2025 Medexus Pharmaceuticals, Inc.
All Rights Reserved.
Facebook Facebook
Privacy Policy Disclaimer Sitemap

Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.